Targeting Siglecs with a sialic acid-decorated nanoparticle abrogates inflammation

Shaun Spence, Michelle K Greene, François Fay, Emily Hams, Sean P Saunders, Umar Hamid, Marianne Fitzgerald, Jonathan Beck, Baljinder K Bains, Peter Smyth, Efrosyni Themistou, Donna M Small, Daniela Schmid, Cecilia M O'Kane, Denise C Fitzgerald, Sharif M Abdelghany, James A Johnston, Padraic G Fallon, James F Burrows, Daniel F McAuleyAdrien Kissenpfennig, Christopher J Scott

Research output: Contribution to journalArticlepeer-review

94 Citations (Scopus)
1167 Downloads (Pure)


Sepsis is the most frequent cause of death in hospitalized patients, and severe sepsis is a leading contributory factor to acute respiratory distress syndrome (ARDS). At present, there is no effective treatment for these conditions, and care is primarily supportive. Murine sialic acid-binding immunoglobulin-like lectin-E (Siglec-E) and its human orthologs Siglec-7 and Siglec-9 are immunomodulatory receptors found predominantly on hematopoietic cells. These receptors are important negative regulators of acute inflammatory responses and are potential targets for the treatment of sepsis and ARDS. We describe a Siglec-targeting platform consisting of poly(lactic-co-glycolic acid) nanoparticles decorated with a natural Siglec ligand, di(α2→8) N-acetylneuraminic acid (α2,8 NANA-NP). This nanoparticle induced enhanced oligomerization of the murine Siglec-E receptor on the surface of macrophages, unlike the free α2,8 NANA ligand. Furthermore, treatment of murine macrophages with these nanoparticles blocked the production of lipopolysaccharide-induced inflammatory cytokines in a Siglec-E-dependent manner. The nanoparticles were also therapeutically beneficial in vivo in both systemic and pulmonary murine models replicating inflammatory features of sepsis and ARDS. Moreover, we confirmed the anti-inflammatory effect of these nanoparticles on human monocytes and macrophages in vitro and in a human ex vivo lung perfusion (EVLP) model of lung injury. We also established that interleukin-10 (IL-10) induced Siglec-E expression and α2,8 NANA-NP further augmented the expression of IL-10. Indeed, the effectiveness of the nanoparticle depended on IL-10. Collectively, these results demonstrated a therapeutic effect of targeting Siglec receptors with a nanoparticle-based platform under inflammatory conditions.

Original languageEnglish
Article number140
Number of pages12
JournalScience Translational Medicine
Issue number303
Publication statusPublished - 02 Sep 2015

Bibliographical note

Author contribution: I porvided expertise on immunological experimental design and in vivo modelling


Dive into the research topics of 'Targeting Siglecs with a sialic acid-decorated nanoparticle abrogates inflammation'. Together they form a unique fingerprint.

Cite this